Valvular & structural heart diseaseCohort study
Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expandable Aortic Transcatheter Valves in the U.S.
- Registry study
- multicentre
Authors' conclusion
MViR with third-generation balloon-expandable aortic transcatheter heart valves is associated with a significant reduction in mitral regurgitation and improvement in symptoms at 1 year, but with elevated valvular gradients and a high reintervention rate.
Study context
- Population
- Patients undergoing mitral valve-in-ring (MViR) after surgical mitral valve repair with an annuloplasty ring, STS/ACC TVT Registry, August 2015–December 2022
- Participants
- 820 patients · 236 sites
Main finding
As reported in the abstract
Outcomes at 1 year after MViR · 1 year
- All-cause mortality at 1 year
- 22.4%
- Reintervention rate
- 9.1%
- NYHA class I to II
- 75.6%
- KCCQ score increase (points)
- 25.9 ± 29.1
- Mean mitral valve gradient (mm Hg)
- 8.4 ± 3.4
- ≤ mild mitral regurgitation
- 91.7%
Observational data: associations, not effects.
Further findings
Procedural and 30-day outcomes
- Transseptal access
- 93.9%
- Technical success
- 88%
- All-cause mortality at 30 days
- 8.3%
Original publication
Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expandable Aortic Transcatheter Valves in the U.S. JACC Cardiovasc Interv. Published 8 April 2024. doi:10.1016/j.jcin.2024.02.012
Summarised from the published abstract; every number is checked against it